Intranasal Glutathione in Parkinson's Disease
Parkinson's Disease (PD)
About this trial
This is an interventional treatment trial for Parkinson's Disease (PD) focused on measuring Parkinson's disease, Neuroprotection, Glutathione, Intranasal
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of Parkinson's Disease made by neurologist within previous 10 years
- Modified Hoehn and Yahr Stage <3
- Age >20
- Subjects must be able to attend study visits at screening, baseline, weeks 4, 8, 12, 16
- Subjects must be able to demonstrate self-administration of study medication or have active caregiver who can administer daily.
- Dose and frequency of all pharmaceutical medications must be stable for one month prior to enrollment.
- Diet, exercise and supplementation must be kept constant throughout participation in study
- Ability to read and speak English
Exclusion Criteria:
- Dementia as evidenced by Montreal Cognitive Assessment (MoCA) <24
- Diseases with features common to Parkinson's Disease (eg. essential tremor, multiple system atrophy, progressive supranuclear palsy)
- Epilepsy
- History of stroke, CVA
- Elevated levels of ALT, AST, BUN or creatinine
- Chronic sinusitis as defined by SNOT-20 score >1.0 on items 1-10.
- Presence of other serious illness
- History of brain surgery
- History of structural brain damage
- History of intranasal telangiectasia
- Supplementation with glutathione and agents shown to increase glutathione will not be permitted and will require a 90 day washout period.
- Pregnant or at risk of becoming pregnant.
Sites / Locations
- Bastyr Clinical Research Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Active Comparator
Placebo Comparator
No Intervention
Intranasal GSH 100mg/ml
Intranasal glutathione 200mg/ml
Saline intranasal delivery
Watchful waiting
Study participant will be provided with monthly supply of study medication and will be asked to intake 100mg/ml of intranasal glutathione (n=15) An amount of 1ml with a frequency 3x per days and duration of 12 weeks with a dosage of 2100mg
Study participant will be provided with monthly supply of study medication and will be asked to intake 200/ml of intranasal glutathione (n=15) An amount of 1ml with a frequency 3x per days and duration of 12 weeks with a dosage of 4200mg
Study participant will be provided with monthly supply of study medication and will be asked to intake Intranasal saline delivery (n=15) An amount of 1ml with a frequency 3x per day with a duration of 12 weeks
No intervention, watchful waiting only (n=4)